Fedex (FDX) Buy Rating Reiterated at Argus; The PT Given is $290.00; Consonance Capital Management LP Upped By $93.64 Million Its Spectrum Pharmaceuticals (SPPI) Stake

December 26, 2017 - By Martha Paddon

Among 37 analysts covering FedEx (NYSE:FDX), 23 have Buy rating, 1 Sell and 13 Hold. Therefore 62% are positive. FedEx has $293.0 highest and $15.50 lowest target. $222.82’s average target is -10.74% below currents $249.64 stock price. FedEx had 102 analyst reports since August 14, 2015 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $184 target in Tuesday, March 15 report. The rating was maintained by Goldman Sachs on Thursday, September 17 with “Conviction-Buy”. The rating was maintained by Credit Suisse with “Buy” on Wednesday, December 20. The stock of FedEx Corporation (NYSE:FDX) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, February 23. The firm has “Buy” rating given on Tuesday, October 10 by KeyBanc Capital Markets. The stock of FedEx Corporation (NYSE:FDX) earned “Outperform” rating by Raymond James on Monday, February 6. The firm has “Sell” rating by Zacks given on Monday, September 7. The firm has “Buy” rating by Citigroup given on Thursday, May 19. The firm has “Neutral” rating given on Friday, September 15 by UBS. Credit Suisse maintained FedEx Corporation (NYSE:FDX) rating on Thursday, December 14. Credit Suisse has “Buy” rating and $278.0 target.

Consonance Capital Management Lp increased Spectrum Pharmaceuticals Inc (SPPI) stake by 331.02% reported in 2017Q3 SEC filing. Consonance Capital Management Lp acquired 6.69 million shares as Spectrum Pharmaceuticals Inc (SPPI)’s stock declined 2.71%. The Consonance Capital Management Lp holds 8.71M shares with $122.54 million value, up from 2.02M last quarter. Spectrum Pharmaceuticals Inc now has $1.84B valuation. The stock increased 2.27% or $0.41 during the last trading session, reaching $18.46. About 650,129 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 20.03% since December 26, 2016 and is downtrending. It has underperformed by 36.73% the S&P500.

Investors sentiment increased to 2.84 in 2017 Q3. Its up 1.89, from 0.95 in 2017Q2. It improved, as 13 investors sold SPPI shares while 19 reduced holdings. 38 funds opened positions while 53 raised stakes. 71.60 million shares or 29.39% more from 55.33 million shares in 2017Q2 were reported. Kennedy Mgmt Inc holds 515,419 shares. Macquarie Grp Incorporated Limited holds 0.04% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 1.48 million shares. State Street Corp invested in 0% or 2.76M shares. Tci Wealth Advsr owns 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 247 shares. Cornerstone Mgmt Hldgs Limited Liability Co stated it has 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Goldman Sachs Inc invested 0.01% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Grantham Mayo Van Otterloo Com Ltd Liability Corporation owns 15,300 shares. Primecap Management Comm Ca holds 4.01 million shares. Massachusetts-based Fmr Ltd has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Citadel Advsrs Ltd Liability Corp has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Acadian Asset Ltd reported 2,525 shares. Wells Fargo & Co Mn holds 949,290 shares or 0% of its portfolio. 19,261 were reported by Mason Street Advsr Limited Liability Company. Susquehanna Gru Llp owns 15,821 shares for 0% of their portfolio. Amalgamated Bankshares accumulated 10,412 shares or 0% of the stock.

Consonance Capital Management Lp decreased Globus Med Inc (NYSE:GMED) stake by 2.28 million shares to 554,699 valued at $16.49M in 2017Q3. It also reduced Myriad Genetics Inc (NASDAQ:MYGN) stake by 1.29M shares and now owns 1.97M shares. Corindus Vascular Robotics I was reduced too.

Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was reinitiated by H.C. Wainwright on Wednesday, August 16 with “Buy”. Zacks upgraded Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rating on Thursday, August 27. Zacks has “Hold” rating and $8.25 target. Jefferies maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Friday, February 10 with “Buy” rating. Jefferies maintained the shares of SPPI in report on Thursday, August 24 with “Buy” rating. RBC Capital Markets maintained it with “Outperform” rating and $13 target in Friday, August 7 report. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 5 report. On Monday, October 9 the stock rating was maintained by Jefferies with “Buy”. The stock of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) earned “Buy” rating by Jefferies on Wednesday, June 7.

FedEx Corporation provides transportation, e-commerce, and business services worldwide. The company has market cap of $66.88 billion. The companyÂ’s FedEx Express segment provides various shipping services for the delivery of packages and freight; international trade services specializing in customs brokerage, and ocean and air freight forwarding services; assistance with the customs-trade partnership against terrorism program; and customs clearance services, as well as an information tool that allows clients to track and manage imports. It has a 22.99 P/E ratio. This segment also publishes customs duty and tax information; and offers transportation management and temperature-controlled transportation services.

Since September 21, 2017, it had 0 buys, and 4 insider sales for $9.61 million activity. $2.20M worth of FedEx Corporation (NYSE:FDX) shares were sold by Colleran Donald F. 11,150 shares were sold by Maier Henry J, worth $2.55M on Thursday, October 26. On Friday, September 29 the insider DUCKER MICHAEL L sold $3.38M. Subramaniam Rajesh had sold 6,750 shares worth $1.48M on Thursday, September 21.

The stock decreased 0.15% or $0.38 during the last trading session, reaching $249.64. About 755,872 shares traded. FedEx Corporation (NYSE:FDX) has risen 19.02% since December 26, 2016 and is uptrending. It has outperformed by 2.32% the S&P500.

Investors sentiment increased to 1.07 in Q3 2017. Its up 0.06, from 1.01 in 2017Q2. It improved, as 49 investors sold FedEx Corporation shares while 378 reduced holdings. 122 funds opened positions while 336 raised stakes. 199.84 million shares or 0.13% less from 200.09 million shares in 2017Q2 were reported. D Scott Neal invested in 0% or 16 shares. Chesley Taft Assoc Limited Co owns 1.09% invested in FedEx Corporation (NYSE:FDX) for 55,780 shares. Levin Strategies Limited Partnership stated it has 0.04% of its portfolio in FedEx Corporation (NYSE:FDX). Paloma Management invested 0.04% of its portfolio in FedEx Corporation (NYSE:FDX). State Of New Jersey Common Pension Fund D holds 230,000 shares. Mathes Co Incorporated stated it has 16,025 shares. Oxbow Advsr Limited Liability accumulated 9,328 shares. Smithfield holds 0.07% or 2,221 shares. Miller Ltd Partnership accumulated 2,500 shares. Caisse De Depot Et Placement Du Quebec has invested 0.05% in FedEx Corporation (NYSE:FDX). Independent has invested 0.75% in FedEx Corporation (NYSE:FDX). Rothschild Il accumulated 9,630 shares or 0.25% of the stock. Lincoln National reported 2,653 shares stake. Spears Abacus Advsrs Ltd Llc invested in 1,100 shares or 0.03% of the stock. Echo Street Management Ltd Liability holds 36,348 shares.